Adaptimmune Reports Third Quarter 2016 Financial Results

- U.S. Food and Drug Administration (FDA) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR™ T-cell therapy; initiation of screening expected in 4Q 2016 -

- Initiated first site for triple tumor study with wholly-owned MAGE-A10 SPEAR T-cells -

- Initiated new patient cohort in synovial sarcoma NY-ESO program -

- Started recruitment of additional patients under amended protocol in ovarian NY-ESO program -

- Executed key agreements with Merck, PCT, and The MD Anderson Cancer Center -

- Adaptimmune reaffirms financial guidance -

- Conference call to be held today at 8:00 a.m. EST (1:00 p.m. GMT) -

PHILADELPHIA and OXFORD, United Kingdom, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the third quarter ended September 30, 2016.

"Adaptimmune has delivered strong momentum since our last update," said James Noble, Adaptimmune's Chief Executive Officer. "We have initiated the first site for a triple tumor study with our wholly-owned MAGE-A10 SPEAR T-cells under our new partnership with MD Anderson, and initiated Cohort 4 in our NY-ESO synovial sarcoma study, as well as commenced recruitment of new patients in our NY-ESO ovarian cancer study under an amended protocol. In addition, we have executed a number of strategic agreements to accelerate our ability to develop, evaluate, and manufacture our affinity enhanced T-cell therapies for patients suffering from a wide array of solid tumor cancers. We are well placed for continued execution and to generate data from studies in multiple cancers with our SPEAR T-cell therapies in 2017."

Mr. Noble continued, "As we recently announced, the FDA has lifted the partial clinical hold on the planned NY-ESO MRCLS study, and we expect to start screening patients shortly. Our goal remains to be the first company to file for approval with a TCR therapy."

If you liked this article you might like

5 Stocks Setting Up for Big Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Biotech Stocks Under $10 Are About to Break Out

5 Stocks Under $10 Set to Soar